Loading
Sonesitatug vedotin is a Claudin 18.2 ADC in phase 3 for gastric cancer, licensed by AstraZeneca from KYM Biosciences.
Sonesitatug vedotin (CMG901) is an anti-Claudin 18.2 antibody carrying the microtubule inhibitor MMAE through a cleavable linker; Claudin 18.2 is a tight-junction protein normally buried in gastric mucosa but exposed on gastric and some pancreatic cancer cells, giving the ADC a tumour-selective address. AstraZeneca licensed global rights from KYM Biosciences in 2023. Phase 1 produced an objective response rate around 33 percent in CLDN18.2-positive gastric cancer, and the CLARITY-Gastric01 phase 3 trial is testing it at 2.2 mg/kg every 3 weeks in second-line gastric cancer. Nausea, vomiting, neutropenia and decreased appetite are the main toxicities, the gut effects reflecting on-target binding to normal stomach lining. It competes with XNW27011 and other CLDN18.2 ADCs, so randomised data will decide the field. It delivers a cell poison to a protein hidden in healthy tissue.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Anti-CLDN18.2 with MMAE. Connects to Claudin 18.2.
1.Antibody binds Claudin 18.2 on the tumour cell surface
Source: clinicaltrials.gov/study/NCT06346392. Doses are for orientation; the current label governs.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2023-02 | Keymed Biosciences (KYM Biosciences) to AstraZeneca CMG901 (sonesitatug vedotin, AZD0901), Claudin 18.2 ADC | Licence | $63m | up to $1.19bn | source |
Compare all products across the US, EU, UK, Japan, China and Australia →
AstraZeneca licenses global rights from KYM Biosciences source
| Adverse event |
|---|
| Nausea |
| Vomiting |
| Neutropenia |
| Decreased appetite |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational (CLARITY-Gastric01) | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Sonesitatug vedotin" OR ABSTRACT:"Sonesitatug vedotin" OR TITLE:"CMG901" OR ABSTRACT:"CMG901" OR TITLE:"AZD0901" OR ABSTRACT:"AZD0901") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sonesitatug vedotin, not a curated reading list.
Shares Claudin 18.2, AstraZeneca, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer.
Shares CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression, Claudin 18.2-positive gastric cancer, Claudin 18.2, Metastatic pancreatic ductal adenocarcinoma.
Shares Claudin 18.2-positive gastric cancer, Metastatic pancreatic ductal adenocarcinoma, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
Shares Claudin 18.2-positive gastric cancer, Metastatic pancreatic ductal adenocarcinoma, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
Shares Claudin 18.2-positive gastric cancer, Claudin 18.2, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
Shares CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression, Claudin 18.2-positive gastric cancer, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression, Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2, Claudin 18.2-positive gastric cancer, Claudin 18.2.
Shares Claudin 18.2, AstraZeneca, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.